Breast cancer, a malignant neoplasm, is the second-most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. In the past, breast cancer occurred less in women in Asia than women in Western countries. However, recent studies show that breast cancer is being diagnosed more frequently in women living in Asia, especially among younger women.

There have been wide-reaching changes in the breast cancer market over the past four decades, particularly in relation to the usage of targeted therapies, which has increased significantly. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies and targeted therapies.

The market is set to be driven by a number of new approvals for drugs and an increased uptake of premium targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.

Scope:

The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.

- What are the competitive advantages of the existing novel drugs?
- Are these targeted therapies used to the same magnitude in all the countries assessed?
- What are the factors contributing to the uptake of these drugs in each country?

With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.

- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
- Which Asia-Pacific countries should expect a late launch and a lower uptake of the late-stage pipeline drugs?

Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Over the 2014-2021 period, the value of the Asia-Pacific markets for breast cancer therapeutics is expected to increase at a compound annual growth rate of 8.5%, from $1.9 billion to over $3.4 billion.

- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the Asia-Pacific markets?
- What are the various trends observed in the market over the forecast period in each of the countries?

Rising breast cancer prevalence and increasing use of premium targeted therapies along with new product approvals will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.

- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
- Various drivers and barriers would influence the market over the forecast period.

- What are the barriers that limit the uptake of premium-priced therapeutics in the accessed countries?
- Which factors are most likely to drive the market in these countries?

Reasons to buy

This report will enable you to -

- Understand the clinical context of breast cancer by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need

- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty

- Consider market opportunities and potential risks by examining trends in breast cancer clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action

- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in breast cancer by examining clinical trial data and multi-scenario product forecast projections

- Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain and Japan

- Discover trends in licensing and co-development deals concerning breast cancer products and identify the major strategic consolidations that have shaped the commercial landscape
4.1.1 Pipeline by Molecular Target
4.2 Clinical Trials
4.2.1 Failure Rate
4.2.2 Patient Enrollment and Clinical Trial Size
4.2.3 Duration
4.3 Competitive Clinical Trials Metrics Analysis

5 Promising Drug Candidates in Pipeline
5.1 Abemaciclib - Eli Lilly
5.1.1 Abemaciclib Forecast
5.2 Buparlisib - Novartis
5.2.1 Buparlisib Forecast
5.3 Lynparza (olaparib) - AstraZeneca
5.3.1 Lynparza Forecast
5.4 Neratinib - Puma Biotechnology
5.4.1 Neratinib Forecast
5.5 Ribociclib - Novartis
5.5.1 Ribociclib Forecast
5.6 NeuVax (nelipepimut-S) - Galena Biopharma
5.7 Veliparib - AbbVie
5.8 Niraparib - Tesaro
5.9 Talazoparib - BioMarin
5.10 Alpelisib - Novartis
5.11 Atezolizumab - Roche
5.12 Entinostat - Syndax
5.13 Margetuximab - MacroGenics
5.14 Taselisib - Genentech
5.15 OBI-822/821 - OBI Pharma
5.16 Heat Map for Pipeline Products

6 Market Forecast to 2021
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Japan
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size

7 Drivers and Barriers for the Disease Market
7.1 Drivers
7.1.1 Increased Uptake of Targeted and Combination Therapies for Breast Cancer
7.1.2 Growth and Aging of Populations to Increase the Incidence
7.1.3 Launch of Premium-Priced Products with Greater Efficacy than Existing Therapies
7.2 Barriers
7.2.1 High Level of Competition
7.2.2 Problems with the Reimbursement of Premium-Priced Therapeutics will Limit their Uptake
7.2.3 Delayed Presentation of Symptoms, Lack of Access and Awareness to Hamper Proper Treatment
7.2.4 Multiple Drugs to Lose Patent Protection in Forecast Period

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 EUSA Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib
8.1.2 Sprint Bioscience Enters Licensing Agreement with Bayer HealthCare
8.1.3 Takeda Enters Licensing Agreement with ImmunoGen
8.1.4 Oncothyreon Enters Licensing Agreement with Array BioPharma for ONT-380
8.1.5 Halozyme Therapeutics Enters Licensing Agreement with Janssen Biotech
8.1.6 CTI BioPharma Enters Licensing Agreement with Servier for Pixuvri
8.2 Co-development Deals
8.2.1 Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration
8.2.2 MacroGenics Enters Agreement with Merck
8.2.3 Color Genomics Partners with University of California Health
8.2.4 Lycera Enters Co-development Agreement with Celgene
8.2.5 Roche Enters Agreement with Oryzon to Develop Epigenetics-Based Medicines
8.2.6 Tracon Enters Co-development Agreement with Santen

9 Appendix
9.1 All Pipeline Drugs by Phase of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 IND/CTA-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Market Forecasts to 2021
9.2.1 Asia-Pacific
9.2.2 China
9.2.3 India
9.2.4 Australia
9.2.5 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Forecasting Model
9.5.6 Deals Data Analysis
9.6 Expert Panel Validation
9.7 Contact Us
9.8 Disclaimer

1.1 List of Tables
Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010-2013
Table 2: Breast Cancer Therapeutics Market, Global, Pipeline Products, Discovery, 2015
Table 3: Breast Cancer Therapeutics Market, Global, Pipeline Products, Preclinical, 2015
Table 4: Breast Cancer Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2015
Table 5: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase I, 2015
Table 6: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase II, 2015
Table 7: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase III, 2015
Table 8: Breast Cancer Therapeutics Market, Global, Pipeline Products, Pre-registration, 2015
Table 9: Breast Cancer Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021
Table 10: Breast Cancer Therapeutics Market, China, Market Forecast, 2014-2021
Table 11: Breast Cancer Therapeutics Market, India, Market Forecast, 2014-2021
Table 12: Breast Cancer Therapeutics Market, Australia, Market Forecast, 2014-2021
Table 13: Breast Cancer Therapeutics Market, Japan, Market Forecast, 2014-2021

1.2 List of Figures
Figure 1: Breast Cancer Therapeutics, Asia-Pacific, Age-Standardized Incidence per 100,000 population), 2012
Figure 2: Breast Cancer Therapeutics, Australia, Age-Specific Incidence Rate per 100,000 Population, 2001, 2006 and 2011
Figure 3: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I-III, 2015
2015


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence
Web Address: http://www.researchandmarkets.com/reports/3627373/
Office Code: SCBRECJU

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number  833 130 83
Sort code  98-53-30
Swift code  ULSBIE2D
IBAN number  IE78ULSB98533083313083
Bank Address  Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World